Ascelia Pharma EBITDA vs. Current Valuation
| ACE Stock | SEK 2.90 0.11 3.65% |
For Ascelia Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ascelia Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ascelia Pharma AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ascelia Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ascelia Pharma AB over time as well as its relative position and ranking within its peers.
Ascelia |
Ascelia Pharma AB Current Valuation vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Ascelia Pharma's current stock value. Our valuation model uses many indicators to compare Ascelia Pharma value to that of its competitors to determine the firm's financial worth. Ascelia Pharma AB is number one stock in ebitda category among its peers. It also is the top company in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ascelia Pharma's earnings, one of the primary drivers of an investment's value.Ascelia Current Valuation vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Ascelia Pharma |
| = | (129.45 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Ascelia Pharma |
| = | 359.6 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Ascelia Current Valuation vs Competition
Ascelia Pharma AB is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 3.46 Billion. Ascelia Pharma retains roughly 359.6 Million in current valuation claiming about 10% of stocks in Biotechnology industry.
Ascelia Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Ascelia Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ascelia Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Ascelia Pharma's change in net profit over the period of time. It can combine multiple indicators of Ascelia Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Ascelia Pharma AB operates as an oncology focused specialty pharmaceutical company that develops medicines to enhance the life expectancy for people living with cancer and cancer-related diseases in Sweden and Denmark. The company was founded in 2000 and is headquartered in Malm, Sweden. Ascelia Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 4 people.
Ascelia Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Ascelia Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ascelia Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ascelia Pharma's important profitability drivers and their relationship over time.
Use Ascelia Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ascelia Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascelia Pharma will appreciate offsetting losses from the drop in the long position's value.Ascelia Pharma Pair Trading
Ascelia Pharma AB Pair Trading Analysis
The ability to find closely correlated positions to Ascelia Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ascelia Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ascelia Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ascelia Pharma AB to buy it.
The correlation of Ascelia Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ascelia Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ascelia Pharma AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ascelia Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Ascelia Pharma position
In addition to having Ascelia Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Non-Metallic and Industrial Metal Mining Thematic Idea Now
Non-Metallic and Industrial Metal Mining
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Non-Metallic and Industrial Metal Mining theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Non-Metallic and Industrial Metal Mining Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Ascelia Stock Analysis
When running Ascelia Pharma's price analysis, check to measure Ascelia Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascelia Pharma is operating at the current time. Most of Ascelia Pharma's value examination focuses on studying past and present price action to predict the probability of Ascelia Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascelia Pharma's price. Additionally, you may evaluate how the addition of Ascelia Pharma to your portfolios can decrease your overall portfolio volatility.